CereVasc Opens New Massachusetts Facility in Preparation for eShunt® System Commercialization

Summary

CereVasc opened a new Massachusetts facility to support commercialization of its eShunt® System following completion of STRIDE Clinical Trial enrollment and $85 million Series C financing. The facility includes ISO Class 7 clean room capabilities for assembly, inspection, testing and manufacturing operations.